MEDICOX Signs Contract with ORAMED to Distribute Oral Insulin in South Korea
- Written by PR Newswire
- MEDICOX secures distribution right for ORAMED's oral insulin in South Korea after phase 3 of FDA approval - Contract scale up to 18 million dollars for developmental milestone and up to 15% royalty for sales - ORAMED says 1 in 7 Korean adults over 30 have diabetes and expects market potential
SEOUL, South Korea, Nov. 18, 2022 /PRNewswire/ -- On...
